SNY Stock Analysis: Buy, Sell, or Hold?
SNY - Sanofi American Depositary Shares (Each representing one-half of one ordinary share)
$41.60
-0.36 (-0.86%)
âŧ
5d:
+2.44%
30d:
+1.61%
90d:
-5.45%
WAIT
LOW Confidence
Analysis Updated: Oct 23, 2026 12:00 AM ET
Earnings: Oct 30, 2026
6d
Get Alerted When SNY Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
âšī¸ NEUTRAL: SNY is fairly priced but lacks strong directional signals. At -2.4% expected growth, valuation appears fair. Wait for clearer setup or better entry on dips.
âšī¸ NEUTRAL: SNY is fairly priced but lacks strong directional signals. At -2.4% expected growth, valuation appears fair. Wait for clearer setup or better entry on dips.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$58.80
Based on 5.5% avg growth
INTRINSIC VALUE TODAY
$36.51
Trading above historical range
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 8.5x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: SNY is currently trading at $41.60, which is considered fair relative to its 30-day fair value range of $39.87 to $42.19. The stock's valuation (Forward PE: 7.9) is in line with its historical norms (8.5). Remarkably, the market is currently pricing in an annual earnings decline of 2.4% over the next few years. This aligns with recent fundamental challenges.
Technical Outlook: Technically, SNY is in a downtrend. The price is approaching resistance at $42.11. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: SNY scores 68/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. Wall Street analysts see significant upside, with an average price target of $53.61 (+28.9%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, SNY is in a downtrend. The price is approaching resistance at $42.11. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: SNY scores 68/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. Wall Street analysts see significant upside, with an average price target of $53.61 (+28.9%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
FAIR
Historical Trading Range
$39.87 -
$42.19
Company Quality Score
51/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
83.3%
All Signals
- NEUTRAL: Price in fair range
- BULLISH: Strong technical setup (68/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 28.9% below Wall St target ($53.61)
- WARNING: Composite score 51/100 in the bottom quintile â this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$39.87 -
$42.19
Current vs Trading Range
FAIR
Support & Resistance Levels
Support Level
$39.07
Resistance Level
$42.11
Current Trend
Downtrend
Technical data as of
Oct 23, 2026
Fundamental Context
Forward P/E (Next Year Est.)
7.88
Wall Street Target
$53.61
(+28.9%)
Revenue Growth (YoY)
14.6%
Earnings Growth (YoY)
-91.2%
Profit Margin
8.1%
Valuation Discount vs History
-2.4% cheaper
PE vs Historical
7.9 vs 8.5
FAIR
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-2.4%
(market-implied from PE analysis)
1-Year Target
$40.60
(-2%)
2-Year Target
$39.63
(-5%)
3-Year Target
$38.68
(-7%)
3-Yr Target (if PE normalizes)
(PE: 8â9)
$41.74
(+0%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 19.9, Growth: 7.1%)
$128.74
(+210%)
Base:
(SPY PE: 7.9, Growth: 7.1%)
$51.05
(+23%)
Bear:
(PE: 6.7, Growth: 7.1%)
$43.40
(+4%)
đ
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (22x PE), but valuation improves significantly next year (8x PE) as earnings recover.
Trailing PE: 21.56 | Current EPS (TTM): $1.90
Bull Case
$90.13
(+115%)
Analyst growth 100.0%, PE expands to 23.7
Base Case
$81.94
(+95%)
Market implied 100.0%, PE stable at 21.6
Bear Case
$27.86
(-34%)
Severe decline -20.0%, PE contracts to 18.3
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
đĄ
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 7.9 to 8.5
Stabilization Target:
$44.90
(+7.9%)
PE Expansion Potential:
+7.9%
Share & Embed Analysis
Last updated: October 23, 2026 5:12 PM ET
Data refreshes hourly during market hours. Next update: 6:12 PM
Data refreshes hourly during market hours. Next update: 6:12 PM
đĨ Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is SNY showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Drug Manufacturers - General Stocks
Top-rated stocks in Drug Manufacturers - General by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ABBV
AbbVie Inc |
STRONG BUY
30 analysts |
$283 | 45 HOLD |
|
LLY
Eli Lilly and Company |
STRONG BUY
31 analysts |
$1328 | 33 SELL |
|
MRK
Merck & Company Inc |
STRONG BUY
27 analysts |
$158 | 56 HOLD |
|
GILD
Gilead Sciences Inc |
STRONG BUY
28 analysts |
$160 | 41 HOLD |
|
BIIB
Biogen Inc |
BUY
36 analysts |
$244 | 43 HOLD |
